Literature DB >> 34142236

Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma.

Fumihiro Terasaki1, Teiichi Sugiura2, Yukiyasu Okamura1, Takaaki Ito1, Yusuke Yamamoto1, Ryo Ashida1, Katsuhisa Ohgi1, Katsuhiko Uesaka1.   

Abstract

PURPOSE: The systemic immune-inflammation index (SII) is a new marker, defined as the platelet count × neutrophil-to-lymphocyte ratio. This study evaluates the SII as a prognostic marker for the overall survival (OS) of patients who underwent pancreatoduodenectomy (PD) for distal cholangiocarcinoma (DCC).
METHODS: One hundred and forty patients who underwent PD for DCC between September, 2002 and December, 2015 at our hospital were divided into a low SII (SII < 1450) group and a high SII (SII ≥ 1450) group. We compared the clinicopathological characteristics and OS of the two groups retrospectively and used multivariate analyses to identify the prognostic factors for OS.
RESULTS: The low and high SII groups comprised 119 and 21 patients, respectively. OS was better in the low SII group than in the high SII group, with median survival times of 81 and 26 months, respectively (p < 0.001). Multivariate analyses revealed that portal vein resection (hazard ratio [HR], 9.58; p < 0.001), SII ≥ 1450 (HR, 2.05; p = 0.041), microscopic venous invasion (HR, 2.04; p = 0.005), and pN1 (HR, 1.73; p = 0.034) were independently associated with poor survival.
CONCLUSION: The SII may be useful for predicting the long-term survival of patients with DCC after PD.
© 2021. Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Distal cholangiocarcinoma; NLR; PLR; Pancreatoduodenectomy; Systemic immune-inflammation index

Mesh:

Substances:

Year:  2021        PMID: 34142236     DOI: 10.1007/s00595-021-02312-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  3 in total

1.  Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma.

Authors:  Sojun Hoshimoto; Shoichi Hishinuma; Hirofumi Shirakawa; Moriaki Tomikawa; Iwao Ozawa; Yoshiro Ogata
Journal:  Oncology       Date:  2019-03-25       Impact factor: 2.935

2.  Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma.

Authors:  Johannes Byrling; Roland Andersson; Agata Sasor; Gert Lindell; Daniel Ansari; Johan Nilsson; Bodil Andersson
Journal:  Ann Gastroenterol       Date:  2017-06-20

3.  Neutrophil-to-lymphocyte ratio as a predictor of postoperative morbidity in patients with distal cholangiocarcinoma.

Authors:  Yusuke Kumamoto; Takashi Kaizu; Hiroshi Tajima; Nobuyuki Nishizawa; Shigenori Ei; Kazuharu Igarashi; Masahiko Watanabe
Journal:  Mol Clin Oncol       Date:  2018-08-14
  3 in total
  3 in total

1.  Use of the Advanced Lung Cancer Inflammation Index as a Prognostic Indicator for Patients With Cholangiocarcinoma.

Authors:  Huasheng Wu; Fadian Ding; Meitai Lin; Zheng Shi; Zhengzhou Mei; Shaoqin Chen; Chao Jiang; Huabin Qiu; Zhenhua Zheng; Youting Chen; Peng Zhao
Journal:  Front Surg       Date:  2022-01-27

2.  Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis.

Authors:  Xue-Chun Liu; Yue-Ping Jiang; Xue-Guo Sun; Jian-Jian Zhao; Ling-Yun Zhang; Xue Jing
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

3.  Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients.

Authors:  Buwen Zhang; Weiyun Yao
Journal:  World J Surg Oncol       Date:  2022-09-29       Impact factor: 3.253

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.